Option chain shows key data for Alpha Teknova's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alpha Teknova.

Alpha Teknova (NASDAQ:TKNO) Stock, Option Chain

Alpha Teknova

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.

News

Intraday Update

Markets

Movers

Trading Ideas

ALHC

AZTA

BRKR

FLEX

GLBE

KEYS

NOVA

RCAT

RERE

TKNO

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday

xr:d:DAFhS-kD63I:2,j:45998648077,t:23042711

ALGM

ALKS

ALLR

ATCH

ATPC

AZTR

BBLG

BLCO

CJET

CONN

CREV

DRMA

ENPH

GERN

GOOGL

KARO

KORE

LITM

MANH

NAAS

NIVF

NUWE

NUZE

Next Technology Holding Inc. - Ordinary Shares

NXTT

PIRS

ROKU

SAGE

SGMO

SLNA

SOAR

SYNX

TSLA

ULTA

VSTM

Vintage Wine Estates, Inc. - Common Stock

WFRD

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

movers image

APLD

AVAH

CMAX

CRWD

DOGZ

EMBC

FTEL

LGCB

LPSN

MEDS

MEIP

MIRA

MNSO

NCPL

NUKK

NWGL

PRTG

PSIG

RYAAY

SAVA

SERV

SLRX

SNOA

SOPA

TELL

VIRI

XCUR

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Alpha Teknova Inc

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

NVDA

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Price Target

Analyst Ratings

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

Guidance

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&amp;D scale to pilot production.

SINT

SINTX  Signs Joint Development Agreement With NED Medical To Develop Next Generation Radiotherapeutic Solutions That May Have Transformative Impact On Cancer Treatment

Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. The company reported quarterly sales of $306.885 million which missed the analyst consensus estimate of $316.950 million by 3.18 percent. This is a 4.07 percent decrease over sales of $319.914 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Shoe Carnival Q3 2024 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $306.885M Miss $316.950M Estimate

GEHC

GE HealthCare Sets Medium-Term 2026-2028 Targets: Organic Revenue Growth Mid-Single Digit (4% - 6%), Adjusted EPS Growth High-Single Digit To Low-Double Digit

Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiates coverage on Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) with a Market Perform rating and announces Price Target of $102.

Keefe, Bruyette & Woods Initiates Coverage On Northeast Bank with Market Perform Rating, Announces Price Target of $102

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

Reiteration

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

GE HealthCare Reiterates 2024 Outlook For Organic Revenue Growth Trending Toward Lower End Of 1% - 2% Range; Continues To See Adjusted EPS $4.25 - $4.35 (Est $4.29)

Contracts

Media

General

Mega Matrix Signed A Memorandum Of Understanding With 9Yards Cinema Production To Jointly Establish An Investment Fund Focused On The Development Of Global Short Drama And Pan-entertainment Sector

Goldman Sachs analyst Catherine O'Brien reinstates AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and announces $119 price target.

Goldman Sachs Reinstates Buy on AerCap Holdings, Announces $119 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alpha Teknova (NASDAQ:<a href="https://investorplace.com/stock-quotes/tkno-stock-quote/">TKNO</a>) just reported results for the second quarter of 2024.<ul><li>Alpha Teknova reported earnings per share of -13 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $9.61 million.</li><li>This was 1.63% better than the analyst estimate for revenue of $9.46 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tkno-stock-earnings-alpha-teknova-for-q2-of-2024/">TKNO Stock Earnings: Alpha Teknova Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TKNO Stock Earnings: Alpha Teknova Beats EPS, Beats Revenue for Q2 2024

Analyst Steven Mah of TD Cowen reiterated a Buy rating on Alpha Teknova (TKNO – Research Report), retaining the price target of $6.00. Steven Mah h...

Alpha Teknova's Stabilizing Operations and Growth Prospects Justify Buy Rating

Conestoga Capital Advisors Q2 2024 Commentary

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

Alpha Teknova, Inc. 2024 Q3 - Results - Earnings Call Presentation

Alpha Teknova (TKNO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from...

Alpha Teknova: Strong Buy Rating Based on Promising Revenue Growth and Strategic Investments

Alpha Teknova, Inc. ( ($TKNO) ) has released its Q3 earnings. Here is a breakdown of the information Alpha Teknova, Inc. presented to its investors...

Alpha Teknova Reports Strong Q3 Revenue Growth

Alpha Teknova GAAP EPS of -$0.15, revenue of $9.6M

Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript

BTIG analyst Mark Massaro reiterated a Hold rating on Alpha Teknova (TKNO – Research Report) today. The company's shares closed yesterday at $7.56....

Comments

Alpha Teknova

Alpha Teknova (TKNO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga